Genmab A/S (GMAB) AI Stock Analysis

Genmab A/S, based in Copenhagen, Denmark, develops antibody therapeutics for cancer and other serious diseases. Key commercialized and partnered products include DARZALEX and daratumumab for multiple myeloma, teprotumumab for thyroid eye disease, ofatumumab for leukemia and multiple sclerosis, and Amivantamab for advanced lung and esophageal cancers. Its development pipeline features candidates such as Epcoritamab, tisotumab vedotin, HexaBody-CD38, and DuoHexaBody-CD37. The company collaborates with several global pharmaceutical partners, including Seagen Inc., AbbVie, Janssen, CureVac AG, BioNTech, and Novo Nordisk A/S.

Genmab's annual revenue rose from $8.42B in FY2021 to $21.53B in FY2024 before falling to $3.72B in FY2025, resulting in a 5-year revenue CAGR of -18.1%. Net income shifted from $7.84B in FY2024 to $963.8M in FY2025, alongside a gross margin decrease from 95.4% to 91.7%. Over the trailing twelve months, revenue totaled $4.13B with an operating margin of 35.2% and EPS of $1.27. In the latest quarter ending June 30, 2026, quarterly revenue expanded 24.9% year-over-year, while quarterly earnings declined 9.4%.

As of June 30, 2026, Genmab held $1.50B in cash and short-term investments alongside total debt of $5.27B, resulting in net debt of $3.77B. Shareholders' equity was $5.96B, supported by a debt-to-equity ratio of 0.89 and a current ratio of 2.46. In FY2025, the business produced $1.19B in operating cash flow and $1.15B in free cash flow, while allocating $37.0M to capital expenditures and $430.3M to share buybacks.

At a last close of $37.00, Genmab trades at a trailing P/E of 29.1x, above the 24.6x median for US-listed Healthcare peers. Its forward P/E of 15.1x sits below the peer median of 17.3x, whereas its EV-to-EBITDA ratio of 20.0x exceeds the peer median of 12.0x. Over the past year, Genmab shares gained 13.0%, underperforming the 16.8% return of the S&P 500. Over five years, the stock dropped 16.7%, trailing the S&P 500 gain of 83.0%.

Consensus ratings include 10 Strong Buy, 1 Buy, and 1 Hold recommendations. The mean price target is $44.40, representing 20.0% upside compared to the last close of $37.00. For the fiscal year ending December 31, 2026, analysts estimate revenue of $29.72B and an EPS of $1.17, which reflects a 34.0% drop in annual earnings per share. Genmab beat EPS forecasts in 2 of the past 4 quarters, and its next earnings report is expected on November 5, 2026.

This page is an AI-written research summary of Genmab A/S (GMAB). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: GMAB income statement, GMAB analyst forecast, GMAB chart. See the GMAB stock overview for the latest quote and news.